InfraReDx Announces The First Patient Enrolled In The PROSPECT II Study On The Detection And Treatment Of The Vulnerable Plaques Suspected To Cause Heart Attacks

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BURLINGTON, Mass.--(BUSINESS WIRE)--Infraredx, Inc., a medical device company committed to advancing the diagnosis of coronary artery disease and prevention of heart attacks, today announced the first patient enrolled in PROSPECT II, a multi-center, prospective study designed to assess the ability of intravascular imaging to identify non-flow obstructing vulnerable plaques. Lipid core plaque (LCP), which is suspected to be vulnerable plaque, is a type of fatty coronary artery plaque implicated in most heart attacks, and will be identified using the Infraredx TVC Imaging System™, a first-in-class dual modality intravascular imaging system. The study’s first patient was enrolled by David Erlinge, MD, PhD, one of the study’s principal investigators, from Lund University in Sweden.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC